Graft versus host disease following liver transplantation: A case report
暂无分享,去创建一个
[1] R. Storb,et al. Prevention of graft-vs.-host disease , 2012, Expert opinion on pharmacotherapy.
[2] G. Garas,et al. Acute graft‐versus‐host disease after liver transplant: Novel use of etanercept and the role of tumor necrosis factor α inhibitors , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[3] A. Palkova,et al. Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease , 2009, The Journal of experimental medicine.
[4] F. Dieli,et al. Analysis of Memory and Effector CD8+ T Cell Subsets in Chronic Graft-versus-Host Disease , 2009, International journal of immunopathology and pharmacology.
[5] G. Behre,et al. Rituximab reduces the incidence of acute graft-versus-host disease. , 2009, Blood.
[6] B. Bierer,et al. Ex Vivo Rapamycin Generates Donor Th2 Cells That Potently Inhibit Graft-versus-Host Disease and Graft-versus-Tumor Effects via an IL-4-Dependent Mechanism1 , 2005, The Journal of Immunology.
[7] R. Storb,et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. , 2004, Blood.
[8] E. Lanino,et al. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation , 2000, Bone Marrow Transplantation.
[9] A. Nademanee,et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. , 1998, Blood.
[10] E D Thomas,et al. 1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.